Profile data is unavailable for this security.
About the company
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
- Revenue in USD (TTM)0.00
- Net income in USD-8.89m
- Incorporated2019
- Employees2.00
- LocationTharimmune Inc1200 Route 22 EastBRIDGEWATER 08807United StatesUSA
- Phone+1 (302) 743-2995
- Fax+1 (302) 645-1280
- Websitehttps://tharimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regen BioPharma Inc | 236.58k | -851.69k | 2.47m | 1.00 | -- | -- | -- | 10.44 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.50m | 2.48m | 13.00 | -- | 0.5252 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| SenesTech Inc | 1.38m | -7.51m | 2.55m | 25.00 | -- | 0.5524 | -- | 1.85 | -15.21 | -15.21 | 0.7189 | 0.8961 | 0.2718 | 0.939 | 13.29 | 55,000.00 | -148.36 | -118.53 | -178.99 | -140.61 | 42.33 | 39.40 | -545.82 | -1,357.86 | 5.69 | -- | 0.0378 | -- | 17.08 | 32.06 | 20.47 | -- | -9.02 | -- |
| Exicure Inc | 500.00k | -13.34m | 2.61m | 6.00 | -- | 1.18 | -- | 5.21 | -1.56 | -1.56 | 0.0582 | 0.2551 | 0.0289 | -- | -- | 83,333.34 | -76.97 | -41.52 | -91.14 | -55.78 | -- | -- | -2,667.20 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 2.65m | 15.00 | -- | 0.1339 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.67m | 2.00 | -- | 0.3791 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -12.48m | 2.69m | 4.00 | -- | -- | -- | -- | -2.46 | -2.64 | 0.00 | -0.3923 | 0.00 | -- | -- | 0.00 | -118.15 | -- | -364.72 | -- | 21.30 | -- | -- | -- | -- | -7.41 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 2.75m | 50.00 | -- | -- | -- | 2.73 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -8.96m | 2.82m | 9.00 | -- | 0.2982 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 2.83m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 2.86m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
| Altamira Therapeutics Ltd | 117.71k | -8.11m | 2.87m | 10.00 | -- | 0.2624 | -- | 24.36 | -31.49 | -26.58 | 0.2396 | 4.88 | 0.0151 | 34.05 | 32.30 | 11,771.21 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Virax Biolabs Group Ltd | 0.00 | -1.71m | 2.88m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -12.40m | 2.88m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 2.90m | 24.00 | -- | -- | -- | 0.2037 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Data as of Jul 05 2024. Currency figures normalised to Tharimmune Inc's reporting currency: US Dollar USD
0.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| XTX Markets LLCas of 31 Mar 2024 | 1.16k | 0.15% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 913.00 | 0.12% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 847.00 | 0.11% |
| Two Sigma Investments LPas of 31 Mar 2024 | 694.00 | 0.09% |
| Warberg Asset Management LLCas of 31 Mar 2024 | 667.00 | 0.09% |
| Tower Research Capital LLCas of 31 Mar 2024 | 100.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 1.00 | 0.00% |
| Virtu Americas LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
